Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Angiography | Research

Innovative angiography: a new approach to discover more hepatic vein collaterals in patients with cirrhotic portal hypertension

Authors: Bowen Liu, Zhendong Yue, Ting Cui, Hongwei Zhao, Lei Wang, Zhenhua Fan, Yifan Wu, Mingming Meng, Ke Zhang, Li Jiang, Huiguo Ding, Yuening Zhang, Fuquan Liu

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The hemodynamics of patients with cirrhosis and portal hypertension are complex and variable. We aimed to investigate differences in venous pressures determined by innovative angiography and conventional angiography using balloon occlusion of the hepatic veins in patients with alcoholic cirrhosis and portal hypertension.

Methods

A total of 134 patients with alcoholic cirrhosis who fulfilled the inclusion criteria from June 2017 to June 2020 were included. During transjugular intrahepatic portosystemic shunt, conventional and innovative angiography were performed, and venous pressures were measured. A paired t-test and Pearson’s correlation coefficient were used for analysis.

Results

Conventional and innovative hepatic angiography detected lateral branches of the hepatic vein in 26 (19.4%) and 65 (48.5%) cases, respectively (P < 0.001). Innovative angiography detected a total of 65 patients with lateral shunts, of whom 37 (56.9%) had initial shunts. The average wedged hepatic venous pressure and portal venous pressure of the initial lateral branches were 21.27 ± 6.66 and 35.84 ± 7.86 mmHg, respectively, with correlation and determination coefficients of 0.342 (P < 0.05) and 0.117, respectively. The mean hepatic venous pressure gradient and portal pressure gradient were 9.59 ± 7.64 and 26.86 ± 6.78 mmHg, respectively, with correlation and determination coefficients of 0.292 (P = 0.079) and 0.085, respectively.

Conclusions

Innovative angiography reveals collateral branches of the hepatic veins more effectively than conventional angiography. Hepatic vein collateral branches are the primary factors leading to underestimation of wedged hepatic venous pressures and hepatic venous pressure gradients, with the initial hepatic vein collateral branches resulting in the most severe underestimations.
Literature
1.
go back to reference Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802–29.CrossRefPubMed Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104:1802–29.CrossRefPubMed
4.
go back to reference Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRefPubMed Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRefPubMed
5.
go back to reference de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefPubMed de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefPubMed
6.
go back to reference Simonetto DA, Liu M, Kamath PS. portal hypertension and related complications: diagnosis and management. Mayo Clin Proc. 2019;94:714–26.CrossRefPubMed Simonetto DA, Liu M, Kamath PS. portal hypertension and related complications: diagnosis and management. Mayo Clin Proc. 2019;94:714–26.CrossRefPubMed
7.
go back to reference Wang T, Liang F, Zhou Z, Qi X. Global sensitivity analysis of hepatic venous pressure gradient (HVPG) measurement with a stochastic computational model of the hepatic circulation. Comput Biol Med. 2018;97:124–36.CrossRefPubMed Wang T, Liang F, Zhou Z, Qi X. Global sensitivity analysis of hepatic venous pressure gradient (HVPG) measurement with a stochastic computational model of the hepatic circulation. Comput Biol Med. 2018;97:124–36.CrossRefPubMed
8.
go back to reference Deplano A, Migaleddu V, Pischedda A, et al. Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection. Dig Dis Sci. 1999;44:155–62.CrossRefPubMed Deplano A, Migaleddu V, Pischedda A, et al. Portohepatic gradient and portal hemodynamics in patients with cirrhosis due to hepatitis C virus infection. Dig Dis Sci. 1999;44:155–62.CrossRefPubMed
9.
go back to reference Osada Y, Kanazawa H, Narahara Y, Mamiya Y, Nakatsuka K, Sakamoto C. Wedged hepatic venous pressure does not reflect portal pressure in patients with cirrhosis and hepatic veno-venous communications. Dig Dis Sci. 2008;53:7–13.CrossRefPubMed Osada Y, Kanazawa H, Narahara Y, Mamiya Y, Nakatsuka K, Sakamoto C. Wedged hepatic venous pressure does not reflect portal pressure in patients with cirrhosis and hepatic veno-venous communications. Dig Dis Sci. 2008;53:7–13.CrossRefPubMed
10.
go back to reference Consensus on clinical application of hepatic venous pressure gradient in China (2018). Chin J Clin Hepatol. 2018;34(12):2526–2536. Consensus on clinical application of hepatic venous pressure gradient in China (2018). Chin J Clin Hepatol. 2018;34(12):2526–2536.
11.
go back to reference Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp. 2020;(160). Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and transjugular liver biopsy. J Vis Exp. 2020;(160).
12.
go back to reference Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Dig Liver Dis. 2011;43:762–7.CrossRefPubMed Merkel C, Montagnese S. Hepatic venous pressure gradient measurement in clinical hepatology. Dig Liver Dis. 2011;43:762–7.CrossRefPubMed
13.
go back to reference Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70:9–29.CrossRefPubMed Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70:9–29.CrossRefPubMed
14.
go back to reference Perelló A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30:1393–7.CrossRefPubMed Perelló A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30:1393–7.CrossRefPubMed
15.
16.
go back to reference Rössle M, Blanke P, Fritz B, Schultheiss M, Bettinger D. Free hepatic vein pressure is not useful to calculate the portal pressure gradient in cirrhosis: a morphologic and hemodynamic study. J Vasc Interv Radiol. 2016;27:1130–7.CrossRefPubMed Rössle M, Blanke P, Fritz B, Schultheiss M, Bettinger D. Free hepatic vein pressure is not useful to calculate the portal pressure gradient in cirrhosis: a morphologic and hemodynamic study. J Vasc Interv Radiol. 2016;27:1130–7.CrossRefPubMed
17.
go back to reference Turco L, Garcia-Tsao G. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis. 2019;23:573–87.CrossRefPubMed Turco L, Garcia-Tsao G. Portal hypertension: pathogenesis and diagnosis. Clin Liver Dis. 2019;23:573–87.CrossRefPubMed
18.
go back to reference Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280–2.CrossRefPubMed Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280–2.CrossRefPubMed
19.
go back to reference Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3:708–19.CrossRefPubMed Qi X, Berzigotti A, Cardenas A, Sarin SK. Emerging non-invasive approaches for diagnosis and monitoring of portal hypertension. Lancet Gastroenterol Hepatol. 2018;3:708–19.CrossRefPubMed
20.
go back to reference Steib CJ, Schewe J, Gerbes AL. Infection as a trigger for portal hypertension. Dig Dis. 2015;33:570–6.CrossRefPubMed Steib CJ, Schewe J, Gerbes AL. Infection as a trigger for portal hypertension. Dig Dis. 2015;33:570–6.CrossRefPubMed
21.
go back to reference Shah V, García-Cardeña G, Sessa WC, Groszmann RJ. The hepatic circulation in health and disease: report of a single-topic symposium. Hepatology. 1998;27:279–88.CrossRefPubMed Shah V, García-Cardeña G, Sessa WC, Groszmann RJ. The hepatic circulation in health and disease: report of a single-topic symposium. Hepatology. 1998;27:279–88.CrossRefPubMed
22.
go back to reference Ferrusquía-Acosta J, Bassegoda O, Turco L, et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. J Hepatol. 2021;74:811–8.CrossRefPubMed Ferrusquía-Acosta J, Bassegoda O, Turco L, et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. J Hepatol. 2021;74:811–8.CrossRefPubMed
23.
go back to reference Silva-Junior G, Baiges A, Turon F, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015;62:1584–92.CrossRefPubMed Silva-Junior G, Baiges A, Turon F, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015;62:1584–92.CrossRefPubMed
24.
go back to reference Monroe EJ, Michalsky WS, Koo KSH, et al. Intrahepatic veno-venous collateralization and misrepresentative hepatic venous pressure gradients in children. Pediatr Radiol. 2020;50:1579–86.CrossRefPubMed Monroe EJ, Michalsky WS, Koo KSH, et al. Intrahepatic veno-venous collateralization and misrepresentative hepatic venous pressure gradients in children. Pediatr Radiol. 2020;50:1579–86.CrossRefPubMed
25.
go back to reference Reverter E, Blasi A, Abraldes JG, et al. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2014;34:16–25.CrossRefPubMed Reverter E, Blasi A, Abraldes JG, et al. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2014;34:16–25.CrossRefPubMed
26.
go back to reference Pomier-Layrargues G, Kusielewicz D, Willems B, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology. 1985;5:415–8.CrossRefPubMed Pomier-Layrargues G, Kusielewicz D, Willems B, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology. 1985;5:415–8.CrossRefPubMed
28.
go back to reference Alvarado-Tapias E, Ardevol A, Garcia-Guix M, et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020;73:829–41.CrossRefPubMed Alvarado-Tapias E, Ardevol A, Garcia-Guix M, et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020;73:829–41.CrossRefPubMed
29.
go back to reference Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.CrossRefPubMed Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61.CrossRefPubMed
30.
go back to reference Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–608.CrossRefPubMed Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–608.CrossRefPubMed
31.
go back to reference Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical treatment for portal hypertension? Lancet. 1980;2:180–2.CrossRefPubMed Lebrec D, Nouel O, Corbic M, Benhamou JP. Propranolol–a medical treatment for portal hypertension? Lancet. 1980;2:180–2.CrossRefPubMed
32.
go back to reference Mandell MS, Durham J, Kumpe D, Trotter JF, Everson GT, Niemann CU. The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg. 2003;97:1573–7.CrossRefPubMed Mandell MS, Durham J, Kumpe D, Trotter JF, Everson GT, Niemann CU. The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension. Anesth Analg. 2003;97:1573–7.CrossRefPubMed
Metadata
Title
Innovative angiography: a new approach to discover more hepatic vein collaterals in patients with cirrhotic portal hypertension
Authors
Bowen Liu
Zhendong Yue
Ting Cui
Hongwei Zhao
Lei Wang
Zhenhua Fan
Yifan Wu
Mingming Meng
Ke Zhang
Li Jiang
Huiguo Ding
Yuening Zhang
Fuquan Liu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02792-6

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine